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Background: Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent
preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa.
Methods: In a prospective study, 982 pregnant women were recruited in Benin and followed until delivery. The
prevalence of point mutations in the pfdhfr and pfdhps genes associated with Plasmodium falciparum resistance to
SP during consecutive antenatal visits was determined. Parasites clearance among women infected at SP intake was
assessed by microscopy and PCR. Association between the persistence of parasites and malaria consequences, were
investigated. Recurrent parasites were genotyped to identify recrudescences from re-infections.
Results: The prevalence of pfdhfr/pfdhps quadruple mutants (triple pfdhfr + single pfdhps) was consistently above
80% while quintuple and sextuple mutants remained low. Importantly the higly mutated parasites apparently never
included the two key mutations, pfdhfr 164 L or pfdhps 540E. Based on PCR results, SP failed to clear existing
parasitaemia in half (48%) of the women who were infected at IPTp schedule. The frequency of recrudescence
reached 76% after the second dose. Women with persistent parasitaemia had an increased prevalence of anaemia
(P = 0.03).
Conclusion: The data presented here, highlight the inability of SP to ensure optimal antiplasmodial protection in
late pregnancy, and invite urgent consideration of an alternative drug or strategy.
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Malaria is an important cause of maternal and
perinatal morbidity and mortality [1]. Pregnancy-
associated malaria (PAM) is characterized by the
accumulation of Plasmodium falciparum-infected erythro-
cytes (PfIE) in placental intervillous spaces [2]. The occur-
rence of low birth weight (LBW) is one of the main
consequences of PAM and this is associated with a* Correspondence: nicaise.ndam@ird.fr
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distribution, and reproduction in any mediumhigh risk of neonatal mortality. Approximately 100,000
children die annually in sub-Saharan Africa due to
malaria-related LBW [3].
In Benin, anti-malarial treatment policy has long been
based on the use of chloroquine (CQ) as first-line and
SP as second-line. CQ was also used in prophylaxis of
malaria during pregnancy. However, decreased thera-
peutic efficacies of both CQ and SP prompted the
change of the national anti-malarial drug policy in 2004
by the official withdrawal of CQ and SP in the treatment
of uncomplicated malaria. As reported in many parts of
the world sulphadoxine-pyrimethamine (SP) has beentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Moussiliou et al. Malaria Journal 2013, 12:195 Page 2 of 9
http://www.malariajournal.com/content/12/1/195used extensively in the past for treatment and prophy-
laxis of falciparum malaria [4]. One of the consequences
is that the utility of SP in the treatment of malaria in
sub-Saharan Africa has declined drastically in the last
decade because of the emergence and spread of drug
resistance of P. falciparum. However, SP is still used for
malaria prevention during pregnancy as intermittent
preventive treatment in pregnancy (IPTp). The SP-IPTp
regimen has been recommended by the World Health
Organization (WHO) [5] since 2004, and was adopted
by Benin the same year. SP-IPTp regimen comprises the
administration of at least two curative doses of SP starting
in the second trimester of pregnancy (16 weeks of gesta-
tion) and ensuring a dose spacing interval of at least one
month. SP continues to be the drug of choice for IPTp both
because it is safe, easy to administer, and because a single
treatment dose has long-lasting prophylactic effect (up to
60 days) [6,7]. SP efficacy is dependent on the number of
mutations accumulated in the genes encoding the P. fal-
ciparum enzymes dihydrofolate reductase (DHFR) and
dihydropteroate synthase (DHPS) [8,9]. Single nucleotide
polymorphisms (SNPs) in the pfdhfr gene, at codons 51, 59,
108, and 164, and in the pfdhps gene, at codons 436, 437,
540, 581, and 613 are associated with in vitro resistance to
pyrimethamine and sulphadoxine, respectively [10-12].
Parasite resistance to SP in vivo is largely associated with a
triple mutation in pfdhfr (resulting in amino acid changes;
N51I, C59R and S108N) coupled with a double mutation in
pfdhps (A437G, K540E) [13-15]. Such P. falciparum
parasites carrying quintuple mutations (triple pfdhfr with
double pfdhps mutations) are highly prevalent in East
Africa [16,17], but rare in West Africa [18], including
Benin where a study from 2003 to 2005 showed that
the most prevalent haplotype (85%) was the quadruple
(triple pfdhfr, single pfdhps) mutant [19]. Although SP
shows poor efficacy in children infected with quintuple
mutant parasites, IPTp with SP seems to remain
effective in preventing the adverse consequences of
malaria on maternal and foetal outcomes in areas
where a high proportion of P. falciparum parasites
carry these quintuple mutations [20,21].
From 2005 to 2007, a study in southern Benin [22]
showed that the proportion of parasites carrying
quadruple pfdhfr/pfdhps mutations during pregnancy
was constantly above 80% whilst no quintuple mutants
were detected. Recently, a prospective cohort study
(STOPPAM) on ~1,000 pregnant women in south-
western Benin, four years after the change of malaria
treatment policy in Benin was conducted. A subset of
samples collected during the follow up were used to
assess the prevalence and possible selection of molecular
markers of SP resistance in the pfdhfr and pfdhps genes
present at different gestational ages, and to characterize
recurrent infections in the context of SP-IPTp.Methods
Study area
The study was conducted from 2008 to 2010 in Comé,
a semi-rural area of southern Benin, 70 km west of
Cotonou, the capital of Benin. Malaria transmission is
perennial, with two peaks during the two rainy seasons.
The entomological inoculation rate (EIR) ranges from
35 to 60 infective bites per person and per year [23],
with P. falciparum predominating [24]. The study area
has been described elsewhere [25].
Study design, collection and handling of blood samples
The study comprised a cohort of pregnant women included
before 24 weeks of pregnancy. Detailed descriptions of the
pregnant women follow-up have been reported elsewhere
[25]. Briefly, 982 women were recruited during the first
antenatal visit and followed up monthly from inclusion to
delivery. Two doses of SP-IPTp (IDA, The Netherlands)
were administered following national guidelines. The exact
gestational age was determined by using an ultrasound
scans, performed with a portable ultrasound system (Titan
Sonosite Bothell WA). A rapid diagnostic test (Parascreen™,
Zephyr Biomedicals Goa, India) for identification of P.
falciparum infection was performed on capillary blood.
Venous blood was taken at inclusion, at each antenatal visit,
and at unscheduled ‘emergency’ visits when women
presented at the clinic for health reasons. At delivery, pla-
cental and peripheral blood was also collected. Thick and
thin blood films were prepared from all blood samples to
confirm active P. falciparum infection, Giemsa-stained, and
read by two independent, experienced microscopists.
Four separate drops of blood were spotted onto
Whatman 3MM filter paper and stored with silica gel
before DNA extraction using the Chelex 100 resin
method [26]. Samples from 212 women were used for
pfdhfr/pfdhps genotyping. A subset of 107 samples based
on the availability of samples from days 7 to 60 following
the SP uptake was identified to assess drug efficacy. Iso-
lates from parasitized women at each SP-IPTp adminis-
tration (either first or second dose) and each sample of
these women until next SP administration, or for a 60-
day period were examined. Women having received
anti-malarial treatment other than SP-IPTp during this
follow up were excluded.
The study was approved by the ethics committees of
the Research Institute for Development (IRD) in
France and the Faculty of Health Science (University of
Abomey-Calavi) in Benin. Written informed consent
was given by all women participating in this study.
Real-time PCR assay for the detection of Plasmodium
falciparum infections
A duplex real-time PCR assay using genus-specific and
species-specific primers and probes (Plasmodium spp/P.
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(18S) of Plasmodium rRNA was used to screen samples
containing parasites following treatment, as described
[27]. Samples underwent 40 cycles of amplification using
the ViiA™ 7 Real-Time PCR system (Applied Biosystem)
and were quantified using a DNA standard range made
from a suspension of in vitro cultured 3D7 P. falciparum
line (obtained through the MR4 as part of the BEI Re-
sources Repository, NIAID, NIH: Plasmodium falcip-
arum 3D7 GL, MRA-1001, deposited by Megan Dowler,
Walter Reed Army Institute of Research).
Nested PCR amplification of pfdhfr and pfdhps genes and
detection of SNPs
Parasite DNA was amplified with outer and nested
specific primers targeting the pfdhfr and pfdhps genes,
as described [28,29]. The SNPs in the pfdhfr and pfdhps
genes were captured using sequence specific oligo-
nucleotide probes-enzyme linked immunosorbent assay
(SSOP-ELISA) technique, as described [29]. Briefly, 96-
well PCR plates (Maxisorp, Nunc, Roskilde, Denmark)
were coated with streptavidin and incubated overnight
at +4°C. Nested PCR products were diluted (1:10), dena-
tured at 95°C and immediately cooled at +4°C before
being incubated on the plate. Individual digoxigenin-
conjugated SSOPs probes targeting pfdhfr codons c50/51
(CI/CN), c59 (C/R), c108 (S/N/T) and c164 (I/L), and
pfdhps codons c436/c437 (AA/AG/SA/SG/FG), c540 (K/
E), c581 (A/G) and c613 (A/S) were added. Plates
were incubated in a shaker-incubator (ES-20/60, Biosan,
Latvia) followed by stringent washing with tetra-methyl-
ammonium chloride (Sigma, Germany). Horseradish
peroxidase-conjugated anti-digoxigenin antibody with o-
phenylene-diamine tablets dissolved in hydrogen perox-
ide was used as substrate. The reaction was stopped by
addition of sulphuric acid. Optical densities (OD) were
read at 492 nm. For each SNP, samples were categorized
into single or mixed infections. Single genotype infec-
tions harboured a single SNP present at OD values
above the threshold of positivity. Mixed genotype sam-
ples contained a main SNP genotype and a minor geno-
type whose OD value was less than half (mixed with
dominant genotype) or more than half (mixed with no
dominant genotype) the OD value of the main genotype.
For samples that contained infections categorized as sin-
gle or mixed with a dominant SNP type at all analysed
codons, results were combined to construct haplotypes.
Molecular genotyping of the polymorphic genes msp1
(block 2) and msp2
Analysis of MSP-2 (3D7 and FC27 allelic families) and
MSP1 block 2 (K1, MAD20 and RO33 allelic families) of
P. falciparum were sequentially performed by nested
PCR in accordance with the genotyping protocol ofSnounou [30]. DNA genotypes of samples collected at
baseline (IPTp uptake) and on the day of recurrent in-
fection were compared according to band size and num-
ber, for each of the allelic families of msp1 block 2 and
msp2. To differentiate new infections from recrudescent
ones, gel photographs were scored by visual comparison
of DNA fragments obtained from baseline and re-
infection samples. Unamplified samples and those show-
ing the same msp2 profile on both consecutive samples
were analysed on the msp1 block 2 markers. An infec-
tion was considered to be a recrudescence when identi-
cal pre-treatment allele(s) were found in post-treatment
samples, the two patterns being either completely identi-
cal or containing some missing or additional clones. In-
fections were considered as re-infections if the allelic
pattern for any of the loci differed completely between
the pre- and post-treatment samples.Data analysis
Data were analysed using STATA version 11 (Stata Corp,
College Station, TX, USA). Descriptive analyses were
done by determining means, medians, standard devia-
tions and interquartile ranges (IQR). The frequency of a
particular mutant or haplotype was calculated as the
proportion of the specific mutant or haplotype among
the total number of samples successfully analysed for
this mutation. Categorical variables were compared
using the Pearson chi-square or Fisher exact test, while
continuous variables were compared by the Kruskall-
Wallis test. The significance level (P = 0.05) was used in
all analyses.Results
In the STOPPAM study, a cohort of 982 women was en-
rolled and followed up, of whom 845 received two doses
of SP, while 16, who were HIV-infected, received three
doses. The first dose of SP-IPTp was given on average at
20 weeks of gestation, with the mean interval between
the two doses of 35.4 days (SD = 9.9). A total of 836
women gave birth to live newborn and successfully com-
pleted the follow up. The parasite prevalence based on
microscopical examination of blood smears was 17.0% at
enrolment, falling to 4.1% one month after the first dose
of SP-IPTp, and remaining stable until one month after
the second SP-IPTp administration, before rising to
11.1% at delivery. Infections were mostly polyclonal with
a multiplicity of infection (MOI) [IQR] of 3.6 [2.2-4.8].
The MOI at IPTp schedules was higher than that of
recurrent infections following treatment (4.5 vs 2.7,
P = 0.04). However no difference was seen in the MOI
following the first or second dose (P = 0.6). Of the 191
women who were parasitized at baseline, 107 fulfilled
the criteria to assess the in vivo drug efficacy (Figure 1).
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antenatal clinic visits
The prevalence of point mutations in the pfdhfr and
pfdhps genes was determined in samples collected from
212 HIV-negative women; their general characteristics
are shown in Table 1. At early pregnancy which corre-
sponds to the day of the enrolment in the study, 88.0%
of isolates consisted of triple mutant pfdhfr haplotypes
CIRNI (C50, N51I, C59R, S108N and I164), 8.4% were
double mutant haplotypes (CICNI and CNRNI), while
3.6% were wild-type CNCSI (Figures 2A and 2B,
Additional file 1: Table S1). This trend remained similar
throughout the study period, as the majority of isolates
(>80%) were of the triple mutant pfdhfr CIRNI
haplotype, and there was no difference in prevalence
according to time of sampling (P = 0.7). For the pfdhps
gene, 81.7% of isolates at early pregnancy were single
mutants SGKAA, 11.6% were double mutant AGKAA
(8.3%) or SGKAS (3.3%), and 6.7% were of the wild-type
haplotype SAKAA. As for pfdhfr, the haplotype distribu-
tion remained similar throughout the follow up, al-
though haplotypes such as AGKAS and AGKGS were
only found late in the follow up, at a prevalence of 6-7%.
At codons pfdhfr I164 and pfdhps K540 only wild types
were found. As expected, combining the two loci re-
vealed that more than 80% of the parasite isolates were
of the quadruple pfdhfr/pfdhps haplotypes (CIRNI-
SGKAA and CIRNI-AGKAA) (Figure 2C). Although in
low proportions (<10%), some less-mutated haplotypes,
as well as more highly mutated quintuple or sextuple al-
lelic haplotypes, were observed, with a tendency forFigure 1 Flowchart diagram of the study.more quintuple and sextuple haplotypes in late preg-
nancy (P = 0.06) (Figure 2C). The quintuple and sextuple
mutants identified were mainly due to the combination
of triple CIRNI pfdhfr mutant haplotype with the double
(SGKAS, AGKAS) and triple (AGKGS) mutants of
pfdhps, respectively.Relationship between pfdhfr and pfdhps haplotypes and
clinical outcome
There was no significant difference in parasite density
among women infected with a particular parasite haplo-
type at any stage of pregnancy: 872 parasites/μl (105
quadruple infections) vs 4,625 parasites/μl (10 quintu-
ple + sextuple infections, P = 0.2). In addition, the dis-
tribution of the various haplotypes detected during
pregnancy and at delivery was not associated with either
risk of placental infection (P = 0.9), maternal anaemia
(P = 0.5), or low birth weight (P = 0.6). Maternal anaemia
was defined as haemoglobin concentration under
11 g/dL and LBW as a birth weight <2,500 g.Identification and analysis of recurrent infections
following IPTp uptake
A total of 107 paired blood samples from women who
had a positive blood smear at SP-IPTp administration
(either first or second dose), and a blood sample avail-
able within a 60-day period following SP treatment were
analysed by real-time PCR. Given the national guidelines
of administration of two doses of SP-IPTp at an interval
of at least one month, the follow-up time after the first
dose of SP-IPT (29 days, range: 7–42) proved generally
shorter than that after the second dose (37 days, range:
13–60, P = 0.007). Parasites were detected in 37 women
(34.5%) by microscopy (blood smear = BS) and in 63
(59.0%) by PCR (Figure 3A, pooled data), of which ap-
proximately one third occurred in the first month after
treatment (11% for BS and 19% for PCR), and two-thirds
in the second month.
Segregating PCR-based data according to the sequence
of the received dose of IPTp showed that the frequency
of recurrence was higher after the second dose (64.6%)
than after the first one (51.5%) (Figure 3B). Women were
then split into those who cleared parasites during the
follow up (BS-/PCR-), those in whom a submicroscopic
parasitaemia persisted (BS-/PCR+) and those in whom a
microscopic parasitaemia persisted (BS+/PCR+). No dif-
ferential effect on birth weight was observed, but a trend
for increased prevalence of maternal anaemia in women
with persistent parasitaemia (P = 0.07) was noted. This
trend was more explained by the extreme categories
(BS-/PCR-) versus (BS+/PCR+) where maternal anaemia
was observed in 52.5% vs 84.7%, respectively (P = 0.03)
(Additional file 2: Table S2).
Table 1 Characteristics of the study population whose
parasites were analysed by pfdhfr, pfdhps, msp1 (block 2),
and msp2 genotyping
Mean (SD) Median Range
Mother’s age in years
(n = 212)*
24.04 (5.98) 22 15-40
Gestational age: weeks
of pregnancy
At inclusion (n = 83) 18 (4.1) 17.4 4.0-25.0
At delivery (n = 88) 39.0 (1.9) 39.1 33.4-42.3
First dose SP-IPTp§ intake
(n = 39)
20.9 (3.2) 21 15-28.4
Second dose SP-IPTp intake
(n = 57)
26.5 (3.4) 26.3 20-33.4
Post second dose IPTp
(n = 35)
30.5 (3.5) 31 20-35.9
Newborn’s birth weight in g
(n = 212)
2,881.2 (488.2) 2,900 1,100-4,050
Footnote: * Primigravidae (n = 63), Secundigravidae (n = 54),
Multigravidae (n = 95).
§ SP-IPTp, Sulphadoxine-pyrimethamine used for intermittent preventive
treatment during pregnancy.
Figure 2 Proportions of SNPs associated with SP resistance. DNA from
FRC3, K1, HB3, DD2, 7G8) were used as positive controls. Panel A: Proportio
S436A, A437G, K540E, K613S/T and A581G. SGKAA, AGKAA are single muta
infections were excluded in the derivation of allelic haplotypes. Panel B: Pr
N51I, C59R, S108N and I164L. Proportions are shown for isolates collected a
haplotypes while CIRNI represents triple mutant. Panel C: Proportions of co
both loci revealed that more than 80% of the parasite isolates had quadrup
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A total of 62 pairs of pre- and post-treatment infections
identified by PCR were sequentially genotyped by ampli-
fying the msp2 and msp1 (block 2) genes. Among these
sample pairs, 52 (84.0%) were successfully genotyped.
The mean parasitaemia of recurrent samples among un-
resolved infections, as estimated by real-time PCR, was
lower than in those successfully genotyped (40 vs 1,000
parasites/μL, P < 0.01), explaining the failure to genotype
some recurrences. Overall, recrudescent infections were
more frequent than new infections (57.6% vs 42.3%).
The frequency of recrudescence was markedly higher
after the second SP-IPTp dose (75.9% of re-infections)
than after the first (34.8%) (Figure 4).
The pfdhfr/pfdhps haplotype analysis of this sub-group
of consecutively collected parasite isolates showed a
doubling in the frequency of quintuple mutants (from
9.1 to 20.0%) at the expense of quadruple mutants in
post-treatment samples (P = 0.06), suggestive of a
treatment-based selection effect (Figure 5).
Discussion
Historically, the SP drug combination has been widely
used in malaria-endemic countries of sub-Saharan Africalaboratory strains with known pfdhfr and pfdhps haplotypes (3D7,
n of SNPs associated with SP resistance on pfdhps gene: codons
nt haplotypes while AGKGS represents double mutant. Mixed
oportions of SNPs associated with SP resistance on pfdhfr gene: codons
t different time-points. CICNI, CNRNI and CNRTI are double mutant
mbined pfdhfr and pfdhps allelic haplotypes. The combined analysis of
le pfdhfr/pfdhps allelic haplotypes.
Figure 3 Prevalence rates of recurrent infections. Plasmodium parasites were counted against 200 leukocytes with a 100 × objective lens
under oil immersion. Each qPCR reaction mixture contained 5 μL DNA template in a final volume of 20 μL, 10 μL of Master Mix (Applied
Biosystem), both the genus-specific and P. falciparum specific primers and probes detection system (Plasmo/Pf) as described [24]. Panel A:
Prevalence rates of recurrent infections assessed by microscopy (BS) and PCR. Data are shown as pooled (covering the two months following
treatment) or split into first and second month (days 7–30 or 31–60). Panel B: Prevalence rates of recurrent infections assessed by PCR according
to the IPTp dose received. Data are shown as pooled (covering the two months following treatment) or split into first and second month (days
seven-30 or 31–60).
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malaria. The emergence and widespread development of
P. falciparum resistance to SP occurred over the last
30 years to reach the currently unacceptable level
[31-37]. Characterization of the SNPs associated with SP
resistance has provided an epidemiological tool to inves-
tigate the extent of resistance, as an alternative to the
expensive and labour-intensive in vivo and in vitro drug
sensitivity tests. Clearly, intensive past use of SP has
been responsible for this spread of SP resistance, and to
the upward trend in the prevalence rates of highly mu-
tated pfdhfr/pfdhps parasites in West and East Africa
[36,38]. The current study offered an excellent oppor-
tunity to investigate the level of penetration and theFigure 4 Proportions of recrudescent and new infections
following SP treatment according to the sequence of
IPTp uptake.dynamics of the critical SNPs associated with SP resist-
ance in a longitudinal analysis of P. falciparum isolates
collected from pregnant women using SP-IPTp in Benin.
Based on blood smear, the highest prevalence rate of
P. falciparum infections (17%) was observed at inclusion
when women were screened for the first time, and had
not yet received any anti-malarials, SP or other. Regard-
less of gestational age, the overwhelming majority of
parasite isolates (~ 90%) carried the triple mutant pfdhfr
(CIRNI) haplotype in association with the single pfdhps
(SGKAA) mutation. A similarly high prevalence of
pfdhfr/pfdhps mutations (85%) before any administration
of SP-IPTp was reported in Southern Benin [22]. The
current study provides an update of the situation six
years after the withdrawal of SP as first-line anti-malarial
drug, and three years after the study by Bertin [22], andFigure 5 Prevalence of pfdhfr/pfdhps haplotypes in consecutive
parasite samples at baseline and after IPTp uptake.
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unchanged despite the reduced SP drug pressure on the
parasite population. The identification of pfdhps codons
581 and 613 mutants is in agreement with published
data, which indicates a comparatively low prevalence of
these mutations [18]. Although, any significant relation-
ship between the highly mutated haplotypes, such as the
quintuple and sextuple mutants, with the occurrence of
LBW and maternal anaemia was revealed, there is a ten-
dency for the association of these mutants with higher
peripheral parasite densities despite the limited sample
size.
Of even greater concern, perhaps, is the fact that SP-
IPTp failed to clear almost half of the infections overall,
and that a large proportion of those occurred after com-
pletion of the second dose of SP-IPTp. In this study, the
parasitological failure rate of SP, when analysed within a
month, was 11 and 19% as determined by microscopy
and PCR, respectively (Figure 2A). This is of course far
lower than the failure rate of 73% reported among chil-
dren less than five years old in the same region of Benin
with a 28-day follow up [39], but entirely consistent with
that reported in Tanzania where the failure rate at
28 days after SP treatment was 16% among pregnant
women versus 80% in under five-year old children [40].
The substantially lower failure rates in pregnant women
than in children is attributable to the stronger acquired
anti-malarial immunity in adults, as well as possible
pregnancy-specific differences in pharmacokinetics [41].
The extended follow up (60-day) in this study allowed
detection of a greater number of recurrences, reaching
66% by PCR after the second dose of SP-IPTp. Clearly a
longer follow up equates to less circulating drug and
more exposure to re-infections. The longer follow up
nevertheless also increased the ability to detect true
recrudescence. Up to 76% of recurrent infections
corresponded to true recrudescence. The fact that
most of these infections were submicroscopic suggests
that SP significantly reduced parasite densities, without
complete clearance. The increasing parasite prevalence
observed in the cohort during the third trimester, sev-
eral weeks after the last SP-IPTp dose, is likely to be
related to SP’s lack of efficacy. The effects of such sub-
microscopic infections at various gestational ages on
the health of mother and foetus remain unknown. In
this study, a clear relationship with birth weight, prob-
ably due to low sample size was unable to be demon-
strated, but a trend towards more maternal anaemia
was observed. A recent WHO review [21] concluded
that, despite the high proportion of P. falciparum para-
sites carrying quintuple mutations, associated with
in vivo SP resistance in some African countries, SP-
IPTp remains effective in preventing the adverse con-
sequences of malaria on maternal and foetal outcomes.A previously report showed that the incidence of mal-
aria attacks, i e, symptomatic episodes, in the entire
STOPPAM cohort reached a peak in the third trimes-
ter, long after the intake of the second dose of SP-IPTp
[25]. This observation, allied to the current findings,
indicates that the completion of the two-dose SP-IPTp
regimen at a comparatively early gestational age left
women susceptible to (re-)infection before delivery.
Despite a decline from 17 to 4% in the prevalence of
peripheral parasitaemia after treatment, the occurrence
of recrudescent infections contributes to the rise in the
prevalence later in pregnancy, as evidenced by the 11%
prevalence found at delivery.Conclusions
These findings thus lend weight to the previous argu-
ment [42] for modification of the current SP-IPTp strat-
egy to three doses instead of two in all mothers, as a
third dose may contribute to maintaining low parasite
densities and subdue adverse clinical outcomes. This is
in line with a recently published meta-analysis from
seven trials of 6,281 pregnancies in Africa, showing that
the addition of a third SP dose was associated with an
increase of birth weight and a lower risk of LBW than
the standard two-dose regimen [43].
However, the high rate of recrudescence observed here
highlights the lack of efficacy of SP in pregnant women.
Under such conditions, changing the IPTp regimen
using SP may seem to be based on pragmatic observa-
tions, but will only shift the problem as SP resistance
will increase further. The urgency remains to find a
more suitable alternative drug or a vaccine.Additional files
Additional file 1: Table S1. Constructed haplotypes of pfdhfr and
pfdhps detected during the follow-up.
Additional file 2: Table S2. Clinical comparisons between women with
and without persisting parasitaemia.Abbreviations
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